rf-fullcolor.png

 

December 18, 2013
by Alexander Gaffney, RAC

FDA Issues Change to Make it Easier to Submit Citizen Petitions

It's about to become a lot easier to submit Citizen Petitions to the US Food and Drug Administration (FDA), the agency has announced.

The petitions are essentially formal requests made to FDA to take an action-approve a product, declare that a product was not withdrawn from the market for safety reasons, institute a new policy, or even refrain from approving a generic drug product based on potential problems.

The wide range of potential uses for the petitions makes them a staple of many companies, trade groups, law firms and advocacy groups.

There's just one problem: Filing them can be extremely difficult. While comments may be submitted to FDA electronically, at present Citizen Petitions must be submitted in writing.

"The current regulation does not recognize electronic methods for submitting citizen petitions," FDA explained in an 18 December 2013 Federal Register notice.

Under new modifications to 21 CFR 10, FDA said it will allow Citizen Petitions to be submitted through "electronic methods" while preserving the ability for anyone to submit petitions through existing paper-based methods.

The new section will read as follows:

Electronic submission. Petitions (including any attachments) may be electronically submitted in accordance with paragraph (b)(3) of this section and § 10.20 through http://www.regulations.gov at Docket No. FDA 2013-S-0610. It is only necessary to submit one copy.


Federal Register Notice

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.